The head of the US Food and Drug Administration’s Oncology Center of Excellence sees assuring more diverse clinical trial enrollment as critical to rebuilding “trust” in the clinical trial system and approved medications.
In Trials We Trust: US FDA’s Pazdur Urges Diversity To Build Confidence In Medicine
FDA’s top cancer drug regulator is urging industry to increase diversity in trial populations in the name of re-establishing trust in medicine. A webcast to discuss the topic also showcased a bit of industry trust-building in action.
